Abbott Laboratories (NYSE:ABT) EVP Sells $102,288.30 in Stock

Abbott Laboratories (NYSE:ABT) EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $102,288.30. Following the transaction, the executive vice president directly owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. This represents a 0.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Abbott Laboratories Stock Down 1.9%

Shares of NYSE:ABT opened at $110.97 on Friday. Abbott Laboratories has a fifty-two week low of $105.27 and a fifty-two week high of $139.15. The firm’s 50 day moving average price is $116.39 and its 200 day moving average price is $124.82. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The stock has a market cap of $192.83 billion, a price-to-earnings ratio of 29.83, a price-to-earnings-growth ratio of 1.80 and a beta of 0.74.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the business earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Hedge Funds Weigh In On Abbott Laboratories

Several large investors have recently added to or reduced their stakes in ABT. Brighton Jones LLC boosted its holdings in shares of Abbott Laboratories by 10.1% in the 4th quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker’s stock valued at $5,850,000 after purchasing an additional 4,755 shares during the last quarter. Sivia Capital Partners LLC increased its holdings in Abbott Laboratories by 3.5% during the 2nd quarter. Sivia Capital Partners LLC now owns 4,768 shares of the healthcare product maker’s stock worth $648,000 after purchasing an additional 162 shares during the last quarter. United Bank raised its position in shares of Abbott Laboratories by 7.4% in the 2nd quarter. United Bank now owns 29,004 shares of the healthcare product maker’s stock valued at $3,945,000 after purchasing an additional 2,001 shares in the last quarter. GHP Investment Advisors Inc. boosted its stake in shares of Abbott Laboratories by 0.8% during the 2nd quarter. GHP Investment Advisors Inc. now owns 29,713 shares of the healthcare product maker’s stock valued at $4,041,000 after buying an additional 222 shares during the last quarter. Finally, Versor Investments LP acquired a new stake in shares of Abbott Laboratories during the second quarter worth approximately $408,000. 75.18% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on ABT. William Blair raised Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Oppenheimer cut their price target on shares of Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Weiss Ratings downgraded shares of Abbott Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, January 26th. Daiwa Securities Group lowered their price target on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. Finally, Sanford C. Bernstein reduced their price objective on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $137.05.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.